Monoclonal antibodies for treating cancer

Journal Article · Sun Oct 01 00:00:00 EDT 1989 · Annals of Internal Medicine; (USA)

DOI:https://doi.org/10.7326/0003-4819-111-7-592· OSTI ID:5468367

Dillman, R O ^[1]

---

1. Hoag Cancer Center, Newport Beach, CA (USA)

The purpose of this study is to assess the current status of in-vivo use of monoclonal antibodies for treating cancer. Publications appearing between 1980 and 1988 were identified by computer searches using MEDLINE and CANCERLIT, by reviewing the table of contents of recently published journals, and by searching bibliographies of identified books and articles. More than 700 articles, including peer-reviewed articles and book chapters, were identified and selected for analysis. The literature was reviewed and 235 articles were selected as relevant and representative of the current issues and future applications for in-vivo monoclonal antibodies for cancer therapy and of the toxicity and efficacy which has been associated with clinical trials. Approaches include using antibody alone (interacting with complement or effector cells or binding directly with certain cell receptors) and immunoconjugates (antibody coupled to radioisotopes, drugs, toxins, or other biologicals). Most experience has been with murine antibodies. Trials of antibody alone and radiolabeled antibodies have confirmed the feasibility of this approach and the in-vivo trafficking of antibodies to tumor cells. However, tumor cell heterogeneity, lack of cytotoxicity, and the development of human antimouse antibodies have limited clinical efficacy. Although the immunoconjugates are very promising, heterogeneity and the antimouse immune response have hampered this approach as has the additional challenge of chemically or genetically coupling antibody to cytotoxic agents. As a therapeutic modality, monoclonal antibodies are still promising but their general use will be delayed for several years. New approaches using human antibodies and reducing the human antiglobulin response should facilitate treatment. 235 references.

• OSTI ID: 5468367
• Journal Information: Annals of Internal Medicine; (USA), Vol. 111:7; ISSN 0003-4819
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
MONOCLONAL ANTIBODIES
THERAPEUTIC USES
NEOPLASMS
IMMUNOTHERAPY
RADIOIMMUNOTHERAPY
RADIOTHERAPY
MAN
MICE
RADIOISOTOPES
REVIEWS
ANIMALS
ANTIBODIES
DISEASES
DOCUMENT TYPES
IMMUNOLOGY
ISOTOPES
MAMMALS
MEDICINE
NUCLEAR MEDICINE
PRIMATES
RADIOIMMUNOLOGY
RADIOLOGY
RODENTS
THERAPY
USES
VERTEBRATES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)